PHARMACOLOGY FACULTY
Alan Frazer
 
 
Selected Publications

Alan Frazer

Professor of Pharmacology and Psychiatry

Chair of Pharmacology

Ph.D., University of Pennsylvania

Office: 210-567-4205
Email: frazer@uthscsa.edu

 
 
 

Reseach Interests

• antidepressants • norepinephrine
• serotonin transporters                     • vagal nerve stimulation
 

Research Activities

My primary research interest is the mechanism of action of antidepressant drugs. Historically, the focus of my lab has been to study how chronic treatment of rats with antidepressants affects the functioning of two monoamine systems, noradrenergic and serotonergic, that are important targets for their clinical effects. More recently, our interest in treatment refractory depression caused us to study two treatments for it. One, vagal nerve stimulation, is approved by the FDA whereas the other, ketamine, is more experimental. Our studies have focused on both the mechanisms of action of these treatments and the circuits in brain necessary for their beneficial effects. The latter studies have been carried out in collaboration with Dr. Daniel Lodge in this Department, using state-of-the-art techniques such as optogenetics and designer receptors exclusively activated by designer drugs (DREADDs). A Research Assistant Professor in my lab, Dr. Flavia Carreno (pictured below), has been the lead investigator for these studies. This work led us to study effects of selective negative allosteric modulators of α5-GABAA receptors, such as L-655,708. We found such drugs to have antidepressant-like effects similar to ketamine but not to have ketamine’s adverse effect profile. Finally, in collaboration with another faculty member, Dr. David Morilak, we are studying both cognitive and emotional behaviors in animal models of depression and PTSD and the effect that antidepressant treatments have on such behaviors.

 


Frazer Research Pic
Frazer Research Pic


• Appointments, Boards, Committees and Memberships •

Dr. Frazer is a member of numerous societies including the American Society of Pharmacology and Experimental Therapeutics, the American College of Neuropsychopharmacology (of which he has been the President), the International College of Neuropsychopharmacology (CINP), of which he is a Councillor, and the Editor-in-Chief of their official publication, International Journal of Neuropsychopharmacology and the Society of Neuroscience. He is on the Scientific Advisory Board of the Brain and Behavior Research Foundation, which awards NARSAD grants. He has been awarded a Merit Award from NIH and has been a Career Scientist of the Department of Veterans Affairs.


• Research Group •